Biotech Calendar: Key Dates for September

Here's a list of September's potentially stock-moving biotech events
Publish date:



) -- The big boys and girls of Wall Street are still in the Hamptons or Nantucket through Labor Day, but when they return next week, the biotech sector kicks into high gear for a very busy fall season.

To prepare, here is a calendar of important, potentially stock-moving biotech events in September:

Phase III or pivotal registration studies that could report results in September:

  • Vertex Pharmaceuticals' (VRTX) - Get Report hepatitis C drug telaprevir (previously treated patients.)
  • Seattle Genetics' (SGEN) - Get Report SGN-33 in acute myeloid leukemia and brentuximab in Hodgkin's lymphoma.

Sept. 7

FDA advisory panel meeting to review

Forest Lab's


antibiotic ceftaroline for skin and soft tissue infections.

Sept. 10

BioDelivery Sciences

(BDSI) - Get Report

: Presentation of full dataset from a phase II study of BEMA Buprenorphine at Pain Week 2010 conference.

Sept. 11

FDA approval decision:

Questcor Pharmaceuticals'


Acthar gel in seizure disorders.

Sept. 12-15

Interscience Conference on Antimicrobial Agents and Chemotherapy annual meeting. Expect data from

Optimer Pharmaceuticals



Cubist Pharmaceuticals


(CXA-101) and


(GSK) - Get Report


Rodman & Renshaw Annual Global Investment Conference

Sept. 13-14

Morgan Stanley Global Healthcare Conference

Sept. 14

FDA approval decision:

Savient Pharmaceuticals'


Krystexxa for gout.

Sept. 14-15

Baird 2010 Health Care Conference

Sept. 15

FDA advisory panel meeting:

Abbott Labs'

(ABT) - Get Report

obesity drug Meridia (safety review).

Sept. 16

FDA advisory panel meetings:

Arena Pharmaceuticals'

(ARNA) - Get Report

lorcaserin in obesity and


(ALKS) - Get Report

Vivitrol Opioid for opioid addiction.

FDA approval decision:


(AZN) - Get Report

blood thinner Brilinta.

Biocryst Pharmaceuticals

(BCRX) - Get Report

analyst/investor meeting.

Cell Therapeutics

(CTIC) - Get Report

annual shareholders meeting

Sept. 18-22

European Respiratory Society meeting. Investor-worthy data presentations include



and GlaxoSmithKline (Relovair) and




Sept. 20-22

UBS Global Life Sciences Conference

Sept. 20-24

European Association for the Study of Diabetes meeting. Watch for data presentations by


(SNY) - Get Report


Bristol-Myers Squibb

(BMY) - Get Report

and AstraZeneca (dapaglifozin) and

Novo Nordisk

(NVO) - Get Report


Sept. 21

FDA approval decision:


(NVS) - Get Report

multiple sclerosis drug Gilenia.

Sept. 21-25

Transcatheter Cardiovascular Therapeutics conference. Watch for data from


(ATHX) - Get Report


Sept. 27-28

JMP Securities Healthcare Conference

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.